{"id":53226,"date":"2023-01-24T13:03:06","date_gmt":"2023-01-24T12:03:06","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\/"},"modified":"2023-01-24T13:03:06","modified_gmt":"2023-01-24T12:03:06","slug":"fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\/","title":{"rendered":"FDA Accepts Drug Master File, Signifying a New Milestone for Touchlight\u2019s Enzymatic doggybone DNA Technology"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<b><i>Drug Master File simplifies the U.S. regulatory process for utilising Touchlight\u2019s doggybone DNA and accelerates regulatory filings.<\/i><\/b>\n<\/li>\n<li>\n<b><i>doggybone DNA is the first enzymatic DNA platform with a Drug Master File, representing a significant step towards regulatory adoption.<\/i><\/b>\n<\/li>\n<\/ul>\n<p>HAMPTON, England&#8211;(BUSINESS WIRE)&#8211;Touchlight, a biotechnology company pioneering enzymatic DNA production to enable genetic medicines, today announced a ground-breaking new milestone for its enzymatic doggybone DNA (dbDNA\u2122), following the FDA acceptance of the Drug Master File (DMF) for GMP grade dbDNA.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230124005186\/en\/1693182\/5\/Touchlight_logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230124005186\/en\/1693182\/21\/Touchlight_logo.jpg\"><\/a><\/p>\n<p>\nThis achievement marks the first time a DMF has been accepted for an enzymatically produced DNA platform, representing a sign of the growing interest and adoption of enzymatic DNA across the genetic medicine industry.\n<\/p>\n<p>\nThe FDA acceptance of the DMF for GMP grade dbDNA will ensure that customers no longer need to prepare a standalone section in their fillings when dbDNA is used as a starting material or intermediate, saving considerable time and effort of regulatory and QA functions.\n<\/p>\n<p>\nTouchlight\u2019s dbDNA is a minimal, linear, double stranded, covalently closed DNA vector which is produced through an enzymatic manufacturing process as an alternative to bacterial derived plasmid DNA. dbDNA can accommodate genes of interest of up to at least 20kb and is linearly scalable, making it highly adaptable to support a range of genetic medicines and is ideal for the development of mRNA vaccines, therapeutics, viral vector-based gene therapies and beyond. Touchlight\u2019s doggybone DNA technology was utilised for the first time in human clinical studies in 2022, with multiple further studies initiating in 2023.\n<\/p>\n<p>\nTouchlight\u2019s CDMO customers now have the option to gain access to the dbDNA proprietary manufacturing process information through the DMF for their IND submissions in the U.S. This is a direct result of Touchlight\u2019s strategy for regulatory engagement and effort to enable broad utilisation of dbDNA across the genetic medicine industry.\n<\/p>\n<p>\n<b>Satish Muchakayala, Director of Regulatory Affairs, Touchlight commented<\/b> <i>\u201cAchieving FDA acceptance of our DMF is a win-win for Touchlight\u2019s customers and regulators, avoiding duplication of effort at all levels and thereby helping accelerate regulatory submission and approvals.\u201d<\/i>\n<\/p>\n<p class=\"bwalignc\">\n<b>-ENDS-<\/b>\n<\/p>\n<p>\n<b>About Touchlight<br \/>\n<br \/><\/b>Touchlight is a privately-owned CDMO based in London, U.K., focused on the provision of DNA services and manufacture of enzymatically produced <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.touchlight.com%2Fplatform-technology%2Foverview%2F&amp;esheet=53289337&amp;newsitemid=20230124005186&amp;lan=en-US&amp;anchor=doggybone+DNA&amp;index=1&amp;md5=2745dc099e178d9c6c4ee73bafc74730\" rel=\"nofollow noopener\" shape=\"rect\">doggybone DNA<\/a> (dbDNA\u2122) to enable the development of genetic medicines. Touchlight provide rapid, enzymatic DNA development and manufacturing for all advanced therapy production, including mRNA, viral and non-viral gene therapy and DNA API. dbDNA is a minimal, linear, covalently closed structure, which eliminates bacterial sequences. Touchlight\u2019s revolutionary enzymatic production platform enables unprecedented speed, scale, and the ability to target genes with a size and complexity that is impossible with current technologies. Clients can be supported from pre-clinical through development and supply, to licencing and tech transfer for use in-house.\n<\/p>\n<p>\nFind out more at <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.touchlight.com&amp;esheet=53289337&amp;newsitemid=20230124005186&amp;lan=en-US&amp;anchor=www.touchlight.com&amp;index=2&amp;md5=b819557ff2ea1f533a79cc8fcd22a0c7\" rel=\"nofollow noopener\" shape=\"rect\">www.touchlight.com<\/a>\n<\/p>\n<p>\nFollow Touchlight on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Ftouchlight-ltd%2F&amp;esheet=53289337&amp;newsitemid=20230124005186&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=3&amp;md5=009cd29c8093c45748e3363368672701\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a><br \/>Follow @TouchlightDNA on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FTouchlightDNA&amp;esheet=53289337&amp;newsitemid=20230124005186&amp;lan=en-US&amp;anchor=Twitter&amp;index=4&amp;md5=46b17eb77305ca882e130ed404d62f83\" rel=\"nofollow noopener\" shape=\"rect\">Twitter<\/a>\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Touchlight<\/b><br \/>Robin Bodicoat, Head of Marketing<br \/>\n<br \/>E: <a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#116;&#111;&#x3a;&#x69;&#110;f&#x6f;&#64;t&#x6f;&#x75;&#99;h&#x6c;&#105;g&#x68;&#x74;&#46;c&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">i&#110;&#x66;&#x6f;&#64;&#116;&#x6f;&#x75;c&#104;&#x6c;&#x69;g&#104;&#x74;&#x2e;c&#111;&#x6d;<\/a><br \/>T: +44 20 8481 9200\n<\/p>\n<p>\n<b>Instinctif Partners<\/b><br \/>Melanie Toyne-Sewell \/ Adam Loudon<br \/>\n<br \/>E: <a target=\"_blank\" href=\"&#109;&#x61;i&#x6c;&#x74;&#111;&#x3a;t&#111;&#x75;&#99;&#x68;l&#105;&#x67;h&#x74;&#64;&#105;&#x6e;s&#x74;&#x69;&#110;&#x63;t&#105;&#x66;&#46;&#x63;o&#109;\" rel=\"nofollow noopener\" shape=\"rect\">&#116;&#111;&#x75;c&#104;&#x6c;&#x69;g&#104;&#x74;&#x40;i&#110;&#x73;t&#105;&#x6e;&#x63;t&#105;&#x66;&#x2e;c&#111;&#x6d;<\/a><br \/>T: +44 20 7457 2020\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Drug Master File simplifies the U.S. regulatory process for utilising Touchlight\u2019s doggybone DNA and accelerates regulatory filings. doggybone DNA is the first enzymatic DNA platform with a Drug Master File, representing a significant step towards regulatory adoption. HAMPTON, England&#8211;(BUSINESS WIRE)&#8211;Touchlight, a biotechnology company pioneering enzymatic DNA production to enable genetic medicines, today announced a ground-breaking &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-53226","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FDA Accepts Drug Master File, Signifying a New Milestone for Touchlight\u2019s Enzymatic doggybone DNA Technology - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FDA Accepts Drug Master File, Signifying a New Milestone for Touchlight\u2019s Enzymatic doggybone DNA Technology - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Drug Master File simplifies the U.S. regulatory process for utilising Touchlight\u2019s doggybone DNA and accelerates regulatory filings. doggybone DNA is the first enzymatic DNA platform with a Drug Master File, representing a significant step towards regulatory adoption. HAMPTON, England&#8211;(BUSINESS WIRE)&#8211;Touchlight, a biotechnology company pioneering enzymatic DNA production to enable genetic medicines, today announced a ground-breaking ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-24T12:03:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230124005186\/en\/1693182\/21\/Touchlight_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"FDA Accepts Drug Master File, Signifying a New Milestone for Touchlight\u2019s Enzymatic doggybone DNA Technology\",\"datePublished\":\"2023-01-24T12:03:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\\\/\"},\"wordCount\":515,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230124005186\\\/en\\\/1693182\\\/21\\\/Touchlight_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\\\/\",\"name\":\"FDA Accepts Drug Master File, Signifying a New Milestone for Touchlight\u2019s Enzymatic doggybone DNA Technology - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230124005186\\\/en\\\/1693182\\\/21\\\/Touchlight_logo.jpg\",\"datePublished\":\"2023-01-24T12:03:06+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230124005186\\\/en\\\/1693182\\\/21\\\/Touchlight_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230124005186\\\/en\\\/1693182\\\/21\\\/Touchlight_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FDA Accepts Drug Master File, Signifying a New Milestone for Touchlight\u2019s Enzymatic doggybone DNA Technology\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FDA Accepts Drug Master File, Signifying a New Milestone for Touchlight\u2019s Enzymatic doggybone DNA Technology - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\/","og_locale":"en_US","og_type":"article","og_title":"FDA Accepts Drug Master File, Signifying a New Milestone for Touchlight\u2019s Enzymatic doggybone DNA Technology - Pharma Trend","og_description":"Drug Master File simplifies the U.S. regulatory process for utilising Touchlight\u2019s doggybone DNA and accelerates regulatory filings. doggybone DNA is the first enzymatic DNA platform with a Drug Master File, representing a significant step towards regulatory adoption. HAMPTON, England&#8211;(BUSINESS WIRE)&#8211;Touchlight, a biotechnology company pioneering enzymatic DNA production to enable genetic medicines, today announced a ground-breaking ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-24T12:03:06+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230124005186\/en\/1693182\/21\/Touchlight_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"FDA Accepts Drug Master File, Signifying a New Milestone for Touchlight\u2019s Enzymatic doggybone DNA Technology","datePublished":"2023-01-24T12:03:06+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\/"},"wordCount":515,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230124005186\/en\/1693182\/21\/Touchlight_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\/","url":"https:\/\/pharma-trend.com\/en\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\/","name":"FDA Accepts Drug Master File, Signifying a New Milestone for Touchlight\u2019s Enzymatic doggybone DNA Technology - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230124005186\/en\/1693182\/21\/Touchlight_logo.jpg","datePublished":"2023-01-24T12:03:06+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230124005186\/en\/1693182\/21\/Touchlight_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230124005186\/en\/1693182\/21\/Touchlight_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/fda-accepts-drug-master-file-signifying-a-new-milestone-for-touchlights-enzymatic-doggybone-dna-technology\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"FDA Accepts Drug Master File, Signifying a New Milestone for Touchlight\u2019s Enzymatic doggybone DNA Technology"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53226","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=53226"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/53226\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=53226"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=53226"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=53226"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}